Loading…
Reported covered position: Director of Policy & Public Affairs
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2008 · fourth_quarter · Q4
H. Con. Res. 342 S. Con. Res. 88 General Health Care Reform FDA Reform
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2008 · third_quarter · Q3
Source: Senate LDA
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
H. Con. Res. 342 S. Con. Res. 88 General Health Care Reform FDA Reform
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
H. Con. Res. 342 - FDA Resolution S. Con. Res. 88 - FDA Resolution FDA Reform - Reform of FDAMA (Food and Drug Act Statutes)
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Dextromethorphan Distribution Act of 2007
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
H. Con. Res. 342 S. Con. Res. 88 General Health Care Reform FDA Reform
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
Client: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) · Firm: INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
H. Con. Res. 342 - FDA Resolution S. Con. Res. 88 - FDA Resolution FDA Reform - Reform of FDAMA (Food and Drug Act Statutes)
General Issues Pertaining to Medicare and Medicaid
Issues related to pharmacies in general and compounding specifically Issues related to pharmacy products
General Issues pertaining to the export/import of pharmacy products
Issues Relating to Estriol Compounded Medications
H. Con. Res. 342 - FDA Resolution S. Con. Res. 88 - FDA Resolution FDA Reform - Reform of FDAMA (Food and Drug Act Statutes)
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) via INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP)
2008 · third_quarter · RR
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.
Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.